Michael Andreeff, MD
Enriched profileProfessor of Medicine (Department of Leukemia, Division of Cancer Medicine), Paul and Mary Haas Chair in Genetics; Chief, Section of Molecular Hematology and Therapy · The University of Texas MD Anderson Cancer Center
Michael Andreeff is Professor of Medicine (Department of Leukemia, Division of Cancer Medicine), Paul and Mary Haas Chair in Genetics; Chief, Section of Molecular Hematology and Therapy at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,043 publications with 74,861 citations (h-index 139); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Michael Andreeff, MD, is Professor of Medicine (Department of Leukemia, Division of Cancer Medicine), Paul and Mary Haas Chair in Genetics at The University of Texas MD Anderson Cancer Center. The public record shows 2,043 publications with 74,861 citations (h-index 139), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Protein Degradation and Inhibitors. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 8 companies, 20 NIH-funded awards (1985–2025).
- Most recent indexed publication: 2026 · Leukemia
- Top research focus: Acute Myeloid Leukemia Research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 63 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 723.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
Sponsor: M.D. Anderson Cancer Center
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Sponsor: M.D. Anderson Cancer Center
- IUdR/BUdR Cell Cycle Labelling
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 13 Oct 2026
8 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20241 payment
- Boehringer Ingelheim International GmbHProgram year20237 payments$12,350openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20232 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%BCL-2 Inhibitor100%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
20 NIH research awards on record, funded 1985–2025 per NIH RePORTER. The latest:
- 07 Flow Cytometry and Cellular Imaging Facility
University of Tx Md Anderson Can Ctr
FY2025$812,239P30CA016672 - Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
University of Tx Md Anderson Can Ctr
FY2025$460,702R01FD006118 - 07 Flow Cytometry and Cellular Imaging Facility
University of Tx Md Anderson Can Ctr
FY2024$763,839P30CA016672
Congress activity
Updated 13 Oct 2026
319 congress contributions (2004–2025) across AACR, ASCO, ASH, SABCS per OpenAlex. The most recent:
- Abstract 2561: Immune mediated expansion of p53 mutant clonal hematopoiesis following carboplatin treatment
AACR Annual Meeting
AACR2025Co-author - Abstract 4306: KMT2A rearranged acute myeloid leukemia is vulnerable to the combinatorial inhibition of menin and MYC protein degradation
AACR Annual Meeting
AACR2025Co-author - Abstract 553: Drp1 knockdown impairs mitophagy and sensitizes AML cells to venetoclax by inducing apoptosis
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.
Blood cancer discovery
Clinical Trial2026 - All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Journal of clinical oncology
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-andreeff-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/lab/Michael-Andreeff-Lab
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/profile/Michael-Andreeff
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/michael-andreeff-b26aa7b
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/moleculin/videos/michael-andreeff-md-phd-aml-key-opinion-leader-speaks-to-how-annamycin-could-fit/901103058584346
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
onclive.com/authors/michael-andreeff-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
twitter.com/leukemiamda
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile: Michael Andreeff - Professor at UT MDACC
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Doximity
Doximity profile: Dr. Michael Andreeff, MD – Houston, TX, Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Chief
Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗ - Director
Flow Cytometry and Cellular Imaging Core Facility (NCI-funded), MD Anderson Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗ - Principal Investigator
P01 grant "The Therapy of AML" (NCI)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗ - Regular Member
UTHealth Houston Graduate School of Biomedical Sciences (GSBS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center